Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
- 31 January 2006
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 100 (1) , 83-88
- https://doi.org/10.1016/j.ygyno.2005.07.110
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Common risk factors of breast and ovarian cancer: recent viewInternational Journal of Gynecologic Cancer, 2004
- Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2Science, 2003
- Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 StudiesAmerican Journal of Human Genetics, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Prophylactic Oophorectomy in Carriers ofBRCA1orBRCA2MutationsNew England Journal of Medicine, 2002
- Variation in Cancer Risks, by Mutation Position, in BRCA2 Mutation CarriersAmerican Journal of Human Genetics, 2001
- Newer HRT regimensBJOG: An International Journal of Obstetrics and Gynaecology, 1997
- Reproductive and other factors and risk of epithelial ovarian cancer: An australian case‐control studyInternational Journal of Cancer, 1995
- Risk of cancer in women receiving hormone replacement therapyInternational Journal of Cancer, 1989
- Reliability of Women's Histories of Climacteric Oestrogen Treatment Assessed by Prescription FormsInternational Journal of Epidemiology, 1987